Phase 2 Study of Iberdomide Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Latest Information Update: 21 May 2025
At a glance
- Drugs Iberdomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 13 May 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jan 2026.
- 13 May 2025 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2024 Planned number of patients changed from 38 to 42.